Investigational gastric pentadecapeptide

BPC-157

aka Body Protection Compound 157 · Bepecin · PL-10 · PL-14736 · PLD-116

Evidence grade
Grade C: Preliminary human data
for injury/tendon healing and gut repair (injected or oral)
User score everyone · n = 21
US FDA Not approved checked 2026-11-13
WADA 2026 Prohibited (S0) at all times · checked 2026-11-13
EU No data · checked 2026-11-13

Goals: Recovery & injury Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

3 men aged 45–60

small sample · n = 3

Outcome positive 2 of 3 · unclear 2 of 3

Benefits injury healing 2 of 3 · joints / tendons 2 of 3 · recovery 2 of 3 · gut 1 of 3 · sleep 1 of 3 · strength 1 of 3

Side effects none reported

Stopped 0 of 3 Used with other compounds 2 of 3

All men

5 men

small sample · n = 5

Outcome unclear 3 of 5 · positive 2 of 5 · mixed 1 of 5

Benefits injury healing 3 of 5 · joints / tendons 3 of 5 · recovery 3 of 5 · endurance 1 of 5 · gut 1 of 5 · sleep 1 of 5 · strength 1 of 5

Side effects other 1 of 5

Stopped 0 of 5 Used with other compounds 3 of 5

Everyone

21 people

  • Positive: 12 of 21 (57%)
  • Mixed: 3 of 21 (14%)
  • Negative: 1 of 21 (5%)
  • Unclear: 5 of 21 (24%)
Benefits reported of 21
Benefits reported (n = 21)
ItemReports
Injury healing9 of 21 (43%)
Joints / tendons8 of 21 (38%)
Gut5 of 21 (24%)
Recovery4 of 21 (19%)
Inflammation2 of 21 (10%)
Endurance1 of 21 (5%)
Other1 of 21 (5%)
Sleep1 of 21 (5%)
Side effects reported of 21
Side effects reported (n = 21)
ItemReports
Other3 of 21 (14%)
Fatigue2 of 21 (10%)
Headache1 of 21 (5%)
Low mood1 of 21 (5%)
Why people stopped of 21
Why people stopped (n = 21)
ItemReports
Side effects1 of 21 (5%)

Stopped 1 of 21 (5%) Used with other compounds 8 of 21 (38%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “I am a 48 year old man”

  • “Yes, I was able to recover faster and strength training each muscular group double”

  • “severe anhedonia. I haven't never felt anything like it before, completely flat and empty, no energy”

  • “I’ve definitely noticed a reduction in inflammation and some improvements in my gut health and digestion.”

  • “46M - 24 years of chronic back pain. I feel like I've tried everything ... BPC-157, KVP, and PEA are working on the last stages”

  • “I am also taking the Wolverine stack of peptides to see if I heal faster. This is BPC 157 and TB 500.”

  • “Recently took some for 7 weeks post shoulder surgery from a reliable nearby source and it has done wonders”

  • “What I believe to be the common thread across many of these anhedonia events related to BCP-157 is the stacking of peptides and dopaminergic drugs.”

Read summaries and method notes

Read 1. Two distinct 48-year-old men supplied the clearest age-qualified reports, and both were positive: one described major pain, mobility and sleep improvements after seven days, while the other reported faster recovery plus longstanding shoulder, wrist, knee and gastrointestinal improvements during an eight-week BPC-157/TB-500 cycle. In the broader male sample, a 30-year-old man described a strong local musculoskeletal benefit but also cognitive adverse effects, while another stacked-user reported excellent injury/gut effects followed by severe anhedonia and low energy. An oral user reported reduced inflammation and better digestion over two months, with early fatigue that later eased. Benefits therefore clustered around recovery, injury symptoms, joints/tendons and gut complaints, but several reports were stacked with TB-500, CJC/ipamorelin, supplements or other drugs. This is one of the stronger samples in the batch for men 45–60, but it is still too small and confounded to support causal conclusions.

Read 2. Three men aged 45–60: a 46M with 24 years of back pain (positive, stacked with KPV and PEA), a 47M on BPC-157 + TB-500 after hip replacement, and a 48M with spinal injuries at day 7. Across 21 users from 24 threads: 12 positive, 3 mixed, 1 negative, 5 unclear — injury healing, joint/tendon repair, gut improvement (oral 500 mcg/day) and faster recovery. Four users reported CNS effects (anhedonia when stacked with ADHD stimulants, cognitive effects; one TBI patient stopped for migraine, dizziness and exhaustion).

Note 1. Many positive reports involved TB-500 or other compounds. The seven-day 48M report wrote '500 mg per day'; that dose is preserved verbatim rather than corrected.

Note 2. Strong representation of orthopaedic, spine and gut recovery. Several users warn of anhedonia or cognitive blunting when combined with ADHD stimulants.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Synthetic 15-aa pentadecapeptide derived from human gastric juice. The previous top-ranking claim lacks a validated evidentiary basis; marketed healing and gut benefits remain investigational. Core component of the Wolverine Stack.

Proposed mechanism

The pathways below are proposed from cell/animal research, not established mechanisms of clinical benefit. The 7-fold receptor and ROS assertions do not demonstrate human efficacy. Review

  • Stimulates VEGF → angiogenesis (new blood vessel formation)
  • Upregulates ERK1/2, c-Fos, c-Jun, Egr-1 (cell growth, migration)
  • Activates FAK-paxillin pathway in tendon fibroblasts
  • Increases GH receptor expression in tendons up to 7×
  • Modulates NO system: upregulates NOS3 and NOS1, suppresses NOS2 (neuroprotective)
  • Antioxidant via 4 carboxylic groups scavenging ROS

Safety

  • Immunogenicity and ingredient impurities remain concerns.
  • Dyspnea and other spontaneous reports have uncertain causality.
  • Animal clotting and liver-associated signals require qualification.
  • Long-term and reproductive safety and validated contraindications are not established.

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C injury/tendon healing and gut repair (injected or oral)

C stands. Humans have been treated and outcomes reported (16-person retrospective knee series, 12-person uncontrolled cystitis pilot, 2-person IV tolerability pilot), which clears D. Nothing controlled is positive (the only RCT, in ulcerative colitis, is an abstract with an inconclusive result), so B is out. No adequately powered trial has failed, so it is not F.

Human trials · 5

  1. Veljaca 2002/2003 abstracts, same study2002Placebo-controlled phase 1; abstract only 32 people

    Healthy volunteers; 24 active

    Short rectal tolerability study; not an efficacy trial. Source

  2. Ruenzi 2005 abstract2005RCT; double-blind; abstract only 53 people

    Mild-to-moderate ulcerative colitis

    46 completed; between-group confidence interval crossed zero; insufficient efficacy evidence. Source

  3. PMID 343244352021Retrospective chart review; 17 treated, 16 contacted 16 people

    Mixed knee pain; 12 BPC alone, 4 BPC plus thymosin beta-4

    11/12 BPC-only and 3/4 combination recipients recalled improvement; no control or healing assessment. Source

  4. PMID 393255602024Uncontrolled pilot 12 people

    Women with interstitial cystitis unresponsive to prior pentosan polysulfate

    10 reported resolution and 2 reported 80% improvement; no adverse events reported. Source

  5. PMID 401311432025Open-label IV safety pilot 2 people

    Adults previously exposed to IV BPC-157

    No reported side effects or measured biomarker changes over three days; insufficient for general safety. Source

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    2–4 mg intra-articular per treatment in retrospective knee study; experimental exposure Source on a non-primary host — not linked
  • clinical trial
    10 mg total bladder-wall injections in one procedure Source
  • clinical trial
    10–20 mg IV on consecutive days, two-person pilot Source
  • clinical trial
    0.25–2 mg/kg rectal phase 1; 80 mg rectal daily for two weeks in UC abstract Source

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 4.5 out of 5
  • Sleep 4 out of 5
  • Recovery 5 out of 5
  • Cognitive 3 out of 5

Sources

  1. fda.gov/media/193343/download
  2. pubmed.ncbi.nlm.nih.gov/34324435/
  3. pubmed.ncbi.nlm.nih.gov/39325560/
  4. pubmed.ncbi.nlm.nih.gov/40131143/
  5. hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  6. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  7. ema.europa.eu/en/medicines
  8. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  9. govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
  10. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
  11. wada-ama.org/en/resources/world-anti-doping-code-and-international-standards/prohibited-li
  12. fda.gov/media/94155/download
  13. ema.europa.eu/en/medicines?search_api_fulltext=BPC-157
  14. technical-regulation-information-system.ec.europa.eu/en/notification/26638/text/F/EN
  15. precision.fda.gov/ginas/app/ui/browse-substance?search=BPC-157
  16. pmc.ncbi.nlm.nih.gov/articles/PMC12313605
  17. clinicaltrials.gov/study/NCT02637284
  18. clinicaltrials.gov/study/NCT07437547
  19. clinicaltrials.gov/study/NCT07803250

Reddit threads read · 15

7 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.